Amarin Corp Plc (AMRN)

[ziploc_1]

Amarin's task is first and foremost to stop the reason for its failure, which is infringement by generic Vascepa in the U.S...Amarin needs to find a way to switch from Vascepa to MND-2119 both as a solo and as a combo drug...and then to support a marketing effort in the U.S. for them.

After that, Amarin can turn its attention to finding new indications such as Alzheimers, dry eyes, cancer etc.

In order to achieve these goals, a sale of Amarin to a BP is necessary...Otherwise, we are just spinning our wheels.